# Valneva SE: overview VALN · Nasdaq · CIK 1836564 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/valn.md) · [Financials](/companies/valn/financials.md) · [Filings](/companies/valn/filings.md) · [Insiders](/companies/valn/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [348](/filings/0001628280-24-012747.md) | [361](/filings/0001628280-25-014522.md) | [154](/filings/0001628280-26-018808.md) | [170](/filings/0001628280-26-018808.md) | [175](/filings/0001628280-26-018808.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(17.6%)](/filings/0001628280-24-012747.md) | [(31.4%)](/filings/0001628280-25-014522.md) | [(53.4%)](/filings/0001628280-26-018808.md) | [7.9%](/filings/0001628280-26-018808.md) | [(47.0%)](/filings/0001628280-26-018808.md) | | Net margin | % | [(17.6%)](/filings/0001387131-22-003914.md) | [(39.7%)](/filings/0001628280-25-014522.md) | [(66.0%)](/filings/0001628280-26-018808.md) | [(7.2%)](/filings/0001628280-26-018808.md) | [(66.0%)](/filings/0001628280-26-018808.md) | | Diluted EPS | $ per share | [(0.75)](/filings/0001628280-24-012747.md) | [(1.24)](/filings/0001628280-25-014522.md) | [(0.73)](/filings/0001628280-26-018808.md) | [(0.08)](/filings/0001628280-26-018808.md) | [(0.68)](/filings/0001628280-26-018808.md) | | Free cash flow | $m | [(15.3)](/filings/0001628280-24-012747.md) | [(275)](/filings/0001628280-25-014522.md) | [(217)](/filings/0001628280-26-018808.md) | [(81.1)](/filings/0001628280-26-018808.md) | [(57.3)](/filings/0001628280-26-018808.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue; Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/valn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $12.0m | 2,291,666 | | Unchanged | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $4.0m | 763,199 | | New +763,199 | | [GENERAL AMERICAN INVESTORS CO INC](/funds/40417.md) | 2026-06-30 | $1.9m | 354,361 | | Unchanged | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $707.2k | 135,223 | | New +135,223 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $403.8k | 77,214 | | Reduced −815 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $294.0k | 56,217 | | Added +9,292 | | [IRONWOOD INVESTMENT MANAGEMENT LLC](/funds/1127761.md) | 2026-06-30 | $235.7k | 45,064 | | Added +19,929 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $106.1k | 20,294 | | New +20,294 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $79.4k | 15,178 | | New +15,178 | | [VSM Wealth Advisory, LLC](/funds/2050660.md) | 2026-06-30 | $52.3k | 10,000 | | Unchanged | ## Recent filings [All 265 filings](/companies/valn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 14:29 ET | [6-K](/filings/0001628280-26-065954.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-065954 | | 2026-10-08 | 11:57 ET | [6-K](/filings/0001628280-26-065400.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-065400 | | 2026-08-14 | 15:27 ET | [6-K](/filings/0001628280-26-056999.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-056999 | | 2026-08-13 | 14:27 ET | [6-K](/filings/0001628280-26-056525.md) | Report of a foreign private issuer, period 2026-06-30 | 0001628280-26-056525 | | 2026-07-22 | 18:22 ET | [6-K](/filings/0001628280-26-049149.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-049149 | | 2026-06-25 | 15:57 ET | [6-K](/filings/0001628280-26-045398.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-045398 | | 2026-06-05 | 10:36 ET | [6-K](/filings/0001628280-26-041033.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-041033 | | 2026-06-01 | 14:00 ET | [6-K](/filings/0001628280-26-039308.md) | Report of a foreign private issuer, period 2026-12-31 | 0001628280-26-039308 | | 2026-05-13 | 20:49 ET | [6-K](/filings/0001628280-26-034662.md) | Report of a foreign private issuer, period 2026-03-31 | 0001628280-26-034662 | | 2026-05-12 | 21:09 ET | [SCHEDULE 13D/A](/filings/0001104659-26-059496.md) | Ownership report, active investor, amended | 0001104659-26-059496 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-018808.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1836564 - Tickers: VALN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: I0 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.